[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
September 2003

A Systemic Reaction to Patch Testing for the Evaluation of Acute Generalized Exanthematous Pustulosis

Author Affiliations

From the Department of Dermatology, Tel Aviv Sourasky Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. The authors have no relevant financial interest in this article.

Arch Dermatol. 2003;139(9):1181-1183. doi:10.1001/archderm.139.9.1181

Background  Patch tests are considered safe but adverse reactions have been reported.

Observations  A case of acute generalized exanthematous pustulosis (AGEP) provoked by a patch test with acetaminophen is described. Of special interest are the negative patch test results obtained with the offending drug. The case is discussed against the background of the putative mechanisms of AGEP and the reported systemic reactions to patch testing for AGEP.

Conclusions  To our knowledge, this is the first report in the English-language literature of a generalized AGEP-like reaction caused by patch tests carried out to determine the drug eliciting AGEP.

PATCH TESTING is becoming an accepted tool in the differential diagnosis of acute generalized exanthematous pustulosis (AGEP) and the search for the causative agent. Although it is considered safe, adverse reactions have to be anticipated. We report a case of acetaminophen-induced AGEP provoked by a patch test. To our knowledge, this is the first report in the English literature of a systemic AGEP reaction following patch testing.


A 23-year-old woman was admitted to the hospital following exacerbation of a pruritic rash. Three days earlier she had been treated for nasal discharge with Coldex (Teva Pharmaceuticals, Israel), a medication containing acetaminophen, caffeine, phenylephrine, and chlorpheniramine. One day later she developed erythema and itching on the buttocks and groin, and the following day she was given acetaminophen for the persistent itching. She had developed a similar rash 3 years earlier. Otherwise, she was in good general health, took no medications or nutritional supplements, and did not have a history of psoriasis.

The results of a physical examination on admission were normal, with the exception of a bilateral erythematous, maculopapular rash affecting the trunk and proximal limbs, and of numerous nonfollicular pustules on an erythematous base—mainly on the groin, buttocks, and the antecubital and popliteal fossae. Her body temperature was 37.6°C.

Laboratory investigations showed a total white cell count of 17 700/µL, and the differential count showed 71% neutrophils and 6% eosinophils. Blood, urine, throat, and pustule cultures produced negative results, as did a viral serologic test. Chest radiograph results were also normal. A skin biopsy of a pustule on an erythematous base taken from the groin showed neutrophil-containing spongiform subcorneal pustules as well as perivascular infiltrates with neutrophils and eosinophils. The results of direct and indirect lesional immunofluorescence were negative. Upon admission to our department the suspected offending drug was discontinued, and the eruption resolved within 5 days without any medications.

Six months later the patient received patch tests with the ingredients of Coldex, ie, 1% and 10% acetaminophen in petrolatum, 1% and 10% phenylephrine in petrolatum, 1.5% phenylephrine in distilled water, 1% chlorpheniramine in both petrolatum and distilled water, and 0.5% caffeine in petrolatum. On day 2 the reading for the patch containing 1% acetaminophen was 3 tiny papules and the other readings were negative. On days 4 and 7 all readings were negative. On day 7, however, the patient developed a symmetric vesiculopustular eruption on the trunk and extremities. Histologic examination of a skin biopsy sample from one of these lesions revealed papillary edema and perivascular infiltrates with neutrophils and eosinophils. The eruption resolved after 1 week. A patch test 1 month later using only 1% and 10% acetaminophen in petrolatum provoked no reaction on days 2, 4, and 7. But on day 6, the patient developed a rash similar to the one that erupted on day 7 of the previous test. That rash had resolved spontaneously by day 10. Separate patch tests with each of the other ingredients of the suspected drug were negative.


Baker and Rayan1 coined exanthemic pustular psoriasis in 1968 to describe and name the condition, and in 1980 Beylot et al2 proposed pustuloses exanthématiques aiguës généralisées. The latter prevailed, and the condition is now referred to in English as acute generalized exanthematous pustulosis (AGEP).

Drugs trigger off this relatively rare phenomenon in 90% of cases, especially antibiotics and particularly βlactams.3 Other etiologic agents are mercury; viruses, including parvovirus B19, coxsackievirus B4 and coxsackievirus A9, Epstein-Barr virus, cytomegalovirus, hepatitis B virus; and Mycoplasma pneumoniae37 (Table 1).

Partial List of Agents Causing AGEP
Partial List of Agents Causing AGEP

Several pathogenic mechanisms of AGEP have been proposed. Britschgi et al8 suggested the involvement of T cells, which is evidenced by positive patch tests and lymphocyte transformation tests. The cell-bound drug elicits a drug-specific CD4 and CD8 immune reaction producing interleukin 8 and interleukin 5. They, in turn, cause aggregation of neutrophils and eosinophils,8 in addition to their cytotoxic effect on basal cells.9 Based on the positive patch test results, Moreau et al10 proposed that AGEP is a delayed type of hypersensitivity reaction. Another possible mechanism is the production of antigen-antibody complexes induced by an infection or drug that activates the complement system, which in turn causes neutrophil chemotaxis.11,12

Definitive confirmation of a certain drug as the cause of AGEP theoretically can be obtained by rechallenging the patient with the suspected drug. In view of the possible recurrence of the full-fledged eruption, patch test can serve as a substitute mimicking AGEP both clinically and histologically at the patch test site only. The rationale for using patch tests in AGEP is founded mainly on the pathogenesis of AGEP, which, as mentioned above, includes T-cell involvement and a delayed-type hypersensitivity reaction. Wolkenstein et al13 reported positive patch tests in 7 of 14 patients with AGEP13; Watsky14 suggested that rates of positive patch tests may be even higher, but noted that this may reflect a publication bias. Table 1 summarizes the drugs reported to provoke a positive AGEP patch test.15

Although the patch test reaction in most AGEP cases is limited to the test site, there are a few reports of reactions spreading beyond this site, most of them attributed to diltiazem hydrochloride. Nishimura et al16 reported a generalized AGEP-like reaction caused by a patch test with diltiazem; Vincente-Calleja et al17 described the appearance of a diffuse pruritic eruption on the neck, abdomen, and patch test area—which resolved in a few days—after a positive patch test with diltiazem; and Wakelin and James18 reported a positive patch test with diltiazem accompanied by a mild eczematous reaction on both forearms.

Despite the value of patch tests in the diagnosis of AGEP and the determination of the condition's etiology, the method has drawbacks. There is no standardization for the tests whose specificity and sensitivity are yet to be determined. It is well known that sometimes, including in AGEP cases, a patch test can fail to provoke a reaction in a person who is sensitive to the substance tested. There are several reasons for these negative results, especially when the test is performed with specially prepared materials rather than standard test patches. Among the more common reasons are the different mechanisms of action of the drugs being tested, excessively low drug concentration, insufficient amount of drug applied, inappropriate vehicle, degradation of the substance, and UV irradiation of the patch test site.

Our patient experienced a cutaneous reaction after taking a medication containing acetaminophen, caffeine, phenylephrine, and chlorpheniramine. Another administration of acetaminophen severely exacerbated the cutaneous reaction, which resolved a few days after the medication was discontinued. Patch tests with the alleged culprits were deemed negative despite the appearance of 3 tiny papules at the site of application of 1% acetaminophen, because the papules lasted only 48 hours. A test with a 10-fold-higher concentration of acetaminophen was also negative, and the results of the first test with 1% acetaminophen could not be reproduced at a later time. However, with the initial patch test containing all the ingredients of the suspected drug as well as the subsequent one containing acetaminophen alone, the patient experienced a generalized cutaneous reaction consisting of symmetric vesiculopustular lesions on the trunk and extremities that resolved within a few days. On histologic examination, a skin biopsy specimen of one of the vesiculopustules exhibited some of the histological features of AGEP.

Although the patch test results were negative in our case, the reproducible generalized AGEP-like reaction following patch testing with acetaminophen, together with the histological findings, suggest an acetaminophen-induced AGEP in our patient. As mentioned above, acetaminophen has already been reported as a possible cause of AGEP.

In view of the short interval (24 hours) between administration of the offending drug and appearance of the eruption, and the similarity of that rash and the rash she experienced 3 years earlier, it can also be assumed that acetaminophen caused the earlier AGEP as well.

To our knowledge, this is the first report in the English literature of a generalized AGEP-like reaction caused by patch tests carried out to determine the culprit drug in a case of AGEP. Of special interest are the negative patch test results with the offending drug.

Corresponding author and reprints: Sarah Brenner, MD, Department of Dermatology, Tel Aviv Sourasky Medical Center, 6 Weizmann St, Tel Aviv, 64239 Israel (e-mail: derma@tasmc.health.gov.il).

Accepted for publication January 28, 2003.

Baker  HRyan  TJ Generalized pustular psoriasis: a clinical and epidemiological study of 104 cases.  Br J Dermatol. 1968;80771- 793PubMedArticle
Beylot  CBioulac  PDoutre  MS Pustuloses exanthématiques aiguës généralisées: à propos de 4 cas.  Ann Dermatol Venereol. 1980;10737- 48PubMed
Roujeau  JCBioulac-Sage  PBourseau  C  et al.  Acute generalized exanthematous pustulosis: analysis of 63 cases.  Arch Dermatol. 1991;1271333- 1338PubMedArticle
Sidoroff  AHalevy  SBavnick  JNBVaillant  LRoujeau  JC Acute generalized exanthemathous pustulosis (AGEP): a clinical reaction pattern.  J Cutan Pathol. 2001;28113- 119PubMedArticle
Perceau  GDerancourt  CSalmon-Her  Not Available  et al.  Acute generalized exanthematous pustulosis in hypercalcemia.  Ann Dermatol Venereol. 2000;1271090- 1093PubMed
Feio  ABApetato  MCosta  MMSa  JAlcantara  J Acute generalized exanthematous pustulosis due to Coxsackie B4 virus.  Acta Med Port. 1997;10487- 491PubMed
Rouchouse  BBonnefoy  MPallot  BJacquelin  LDimoux-Dime  GClaudy  AL Acute generalized exanthematous pustular dermatitis and viral infection.  Dermatologica. 1986;173180- 184PubMedArticle
Britschgi  MSteiner  UCSchmid  S  et al.  T-cell involvement in drug-induced acute generalized exanthematous pustulosis.  J Clin Invest. 2001;1071433- 1441PubMedArticle
Ohtsuka  TYamakage  SYamazaki  S Acute generalized exanthematous pustulosis: an apoptotic process as suggested by immunohistochemical analysis.  Dermatology. 1998;197188- 189PubMed
Moreau  ADompmartin  ACastel  BRemond  BLeroy  D Drug-induced acute generalized exanthematous pustulosis with positive patch test.  Int J Dermatol. 1995;34263- 266PubMedArticle
De Coninck  ALVan Strubarq  ASPipeleers-Marichal  MA  et al.  Acute generalized exanthematous pustulosis induced by paracetamol.  Dermatology. 1996;193338- 341PubMedArticle
Beylot  CDoutre  MSBeylot-Barry  M Acute generalized exanthematous pustulosis.  Semin Cutan Med Surg. 1996;15244- 249PubMedArticle
Wolkenstein  PChosidow  OFlechet  ML  et al.  Patch testing in severe cutaneous adverse reaction including Steves-Johnson syndrome and toxic epidermal necrolysis.  Contact Dermatitis. 1996;35234- 236PubMedArticle
Watsky  KL Acute generalized exanthematous pustulosis induced by metronidazole: the role of patch testing.  Arch Dermatol. 1999;13593- 94PubMedArticle
De Their  FBlondeel  ASong  M Acute generalized exanthematous pustulosis induced by amoxicillin with clavulanate.  Contact Dermatitis. 2001;44114- 115PubMedArticle
Nishimura  TYoshioka  KKatoh  J  et al.  Pustular drug eruption induced by diltiazem HCL.  Skin Res. 1991;33 (suppl 10) 251- 254PubMed
Vincente-Calleja  JMAguirre  ALanda  NCrespo  VGonzala-Perez  RDiaz-Perez  JL Acute generalized exanthematous pustulosis due to diltiazem: confirmation by patch testing.  Br J Dermatol. 1997;137837- 839PubMedArticle
Wakelin  SHJames  MP Diltiazem-induced acute generalized exanthematous pustulosis.  Clin Exp Dermatol. 1995;20341- 344PubMedArticle